SCHEMBL14968153

SCHEMBL14968153

CCOC(=O)C1CCC(Oc2ncc(Br)cn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.42
MAPK1 P28482 4/20 0.42
MEN1 O00255 3/20 0.42
HSD17B10 Q99714 2/20 0.42
TSHR P16473 4/20 0.42
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
TP53 P04637 1/20 0.42
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
GAA P10253 3/20 0.41
POLB P06746 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
HMOX1 P09601 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
KDM4E B2RXH2 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14971758 0.89 HSD17B10 (0.40) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL14967408 0.89 HSD17B10 (0.40) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL14971705 0.89 HSD17B10 (0.40) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL23961141 0.89 KMT2A (0.43) KMT2AMEN1ALDH1A1MAPTGAA
SCHEMBL17869723 0.84 CYP2C19 (0.49) KMT2AMEN1TSHRALDH1A1MAPT
SCHEMBL14968065 0.83 DGAT1 (0.50) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL669097 0.83 DGAT1 (0.50) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL14968084 0.83 DGAT1 (0.50) KMT2AMAPK1MEN1HSD17B10TSHR
SCHEMBL25504440 0.82 DGAT1 (0.42) MAPK1SMN1; SMN2HMOX1GPR119
SCHEMBL27023021 0.82 DGAT1 (0.42) MAPK1SMN1; SMN2HMOX1GPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2863915-B1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
EP-2863915-B1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS MERCK SHARP & DOHME (US) 2017-12-06 EP disclosed
US-9416111-B2 Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-9416111-B2 Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-9416111-B2 Substituted diazine and triazine spleen tyrosine kinease (Syk) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-08-16 US disclosed
US-20150166486-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS MERCK SHARP & DOHME LLC 2015-06-18 US disclosed
US-20150166486-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS MERCK SHARP & DOHME LLC 2015-06-18 US disclosed
US-20150166486-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS MERCK SHARP & DOHME LLC 2015-06-18 US disclosed
EP-2863915-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-04-29 EP disclosed
WO-2013192088-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-12-27 WO disclosed
WO-2013074387-A1 IMIDAZOLE DERIVATIVES MERCK SHARP & DOHME CORP. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166486-A1 SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINEASE (SYK) INHIBITORS SYK, ZAP70, TYRO3 KMT2A 1064/4885MAPK1 875/4885MEN1 4319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.